Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2012, Article ID 839853, 5 pages
http://dx.doi.org/10.1155/2012/839853
Research Article

The PPAR Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia

1Département de Pharmacologie Médicale, EA 1046, Université Lille Nord de France, 1 place de Verdun, 59000 Lille, France
2Service de Psychiatrie et Addictologie, CHU Lille, 59037 Lille, France
3LNFP, EA4559, Université Lille Nord de France, 59000 Lille, France

Received 13 January 2012; Revised 12 March 2012; Accepted 13 March 2012

Academic Editor: Anilkumar Pillai

Copyright © 2012 Benjamin Rolland et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. van Os and S. Kapur, “Schizophrenia,” The Lancet, vol. 374, no. 9690, pp. 635–645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Malaspina, “Schizophrenia: a neurodevelopmental or a neurodegenerative disorder,” The Journal of Clinical Psychiatry, vol. 67, no. 8, article e07, 2006. View at Google Scholar · View at Scopus
  3. J. A. Lieberman, L. F. Jarskog, and D. Malaspina, “Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection,” Journal of Clinical Psychiatry, vol. 67, no. 6, pp. 983–990, 2006. View at Google Scholar · View at Scopus
  4. S. H. Fatemi and T. D. Folsom, “The neurodevelopmental hypothesis of Schizophrenia, revisited,” Schizophrenia Bulletin, vol. 35, no. 3, pp. 528–548, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. P. McGorry, “Transition to adulthood: the critical period for pre-emptive, disease-modifying care for schizophrenia and related disorders,” Schizophrenia Bulletin, vol. 37, no. 3, pp. 524–530, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Q. Do, J. H. Cabungcal, A. Frank, P. Steullet, and M. Cuenod, “Redox dysregulation, neurodevelopment, and schizophrenia,” Current Opinion in Neurobiology, vol. 19, no. 2, pp. 220–230, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Nishioka and S. E. Arnold, “Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia,” American Journal of Geriatric Psychiatry, vol. 12, no. 2, pp. 167–175, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. S. B. Powell, “Models of neurodevelopmental abnormalities in schizophrenia,” Current Topics in Behavioral Neurosciences, vol. 4, pp. 435–481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. B. K. Lipska, G. E. Jaskiw, and D. R. Weinberger, “Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia,” Neuropsychopharmacology, vol. 9, no. 1, pp. 67–75, 1993. View at Google Scholar · View at Scopus
  10. L. Li, Y. Du, N. Li, X. Wu, and Y. Wu, “Top-down modulation of prepulse inhibition of the startle reflex in humans and rats,” Neuroscience and Biobehavioral Reviews, vol. 33, no. 8, pp. 1157–1167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. D. L. Braff, M. A. Geyer, and N. R. Swerdlow, “Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies,” Psychopharmacology, vol. 156, no. 2-3, pp. 234–258, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. J. G. Howland, D. K. Hannesson, and A. G. Phillips, “Delayed onset of prepulse inhibition deficits following kainic acid treatment on postnatal day 7 in rats,” European Journal of Neuroscience, vol. 20, no. 10, pp. 2639–2648, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. Duarte, A. Kulak, M. M. Gholam-Razaee et al., “N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development,” Biological Psychiatry. In press.
  14. S. Lavoie, M. M. Murray, P. Deppen et al., “Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients,” Neuropsychopharmacology, vol. 33, no. 9, pp. 2187–2199, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. R. Pyper, N. Viswakarma, S. Yu, and J. K. Reddy, “PPARalpha: energy combustion, hypolipidemia, inflammation and cancer,” Nuclear Receptor Signaling, vol. 8, article e002, 2010. View at Google Scholar · View at Scopus
  16. R. S. Rosenson, D. A. Wolff, A. L. Huskin, I. B. Helenowski, and A. W. Rademaker, “Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome,” Diabetes Care, vol. 30, no. 8, pp. 1945–1951, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Olukman, E. D. Sezer, S. Ülker, E. Y. Sözmen, and G. M. Çnar, “Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats,” Experimental Diabetes Research, vol. 2010, Article ID 828531, 10 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Deplanque, P. Gelé, O. Pétrault et al., “Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment,” Journal of Neuroscience, vol. 23, no. 15, pp. 6264–6271, 2003. View at Google Scholar · View at Scopus
  19. D. K. Bhateja, D. K. Dhull, A. Gill et al., “Peroxisome proliferator-activated receptor-a activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms,” European Journal of Pharmacology, vol. 674, pp. 33–43, 2012. View at Google Scholar
  20. K. Marche, T. Danel, and R. Bordet, “Fetal alcohol-induced hyperactivity is reversed by treatment with the PPARα agonist fenofibrate in a rat model,” Psychopharmacology, vol. 214, no. 1, pp. 285–296, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Swamy, K. N. S. Sirajudeen, and G. Chandran, “Nitric oxide (NO), citrullineNO cycle enzymes, glutamine synthetase, and oxidative status in kainic acid-mediated excitotoxicity in rat brain,” Drug and Chemical Toxicology, vol. 32, no. 4, pp. 326–331, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. M. Zhang and B. R. Bhavnani, “Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens,” BMC Neuroscience, vol. 7, article 49, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. D. L. Braff, “Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia,” Current Topics in Behavioral Neurosciences, vol. 4, pp. 349–371, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. S. Keshavan, H. A. Nasrallah, and R. Tandon, “Schizophrenia, “Just the Facts” 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse,” Schizophrenia Research, vol. 127, no. 1–3, pp. 3–13, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Melis, S. Carta, L. Fattore et al., “Peroxisome proliferator-activated receptors-alpha modulate dopamine cell activity through nicotinic receptors,” Biological Psychiatry, vol. 68, no. 3, pp. 256–264, 2010. View at Publisher · View at Google Scholar · View at Scopus